ReviewCancers2026
Computer Vision for Predicting the Efficacy of Neoadjuvant Therapy in Breast Cancer.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Neoadjuvant therapy (NAT) is a standard component of breast cancer treatment, yet response rates vary substantially across patients. Accurate prediction of pathological complete response remains an unmet clinical need to improve patient selection for NAT. This review summarizes current approaches of using computer vision to predict breast cancer response to NAT from histopathological slides. We examined studies employing computer vision and machine learning models on hematoxylin and eosin and immunohistochemically stained whole-slide images, focusing on morphological features of tumor cells, stroma and tumor-infiltrating lymphocytes associated with pathological complete response. Key morphological predictors of therapy resistance included low tumor cell density with cord-like patterns, necrosis, predominance of collagenous and fibroblast-rich stroma and tumor vascularization, while therapy sensitivity was associated with high nuclear staining intensity, high tumor cell density and lymphocyte infiltration. We highlighted the advantages of incorporating multimodal data to enhance predictive performance. Our analysis demonstrates that computer vision models can detect subtle morphological patterns that may be difficult for pathologists to evaluate, providing valuable insights for personalized therapy planning in breast cancer. Further development of cross-modal, interpretable artificial intelligence solutions may improve prediction accuracy and deepen our understanding of tumor biology relevant to NAT response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.